1. Scrip

Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm

 
• By Mandy Jackson

The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.

Medicine stops disease domino effect
Biogen/Eisai's Aduhelm is first to market but other anti-amyloid drugs, like donanemab, will feel the NCD decision impact • Source: Alamy

The biggest milestone of 2022 for Biogen, Inc. and its Alzheimer’s therapy Aduhelm (aducanumab) – a Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) for anti-amyloid antibodies – also is important for Eli Lilly and Company and its drug donanemab. CMS issued its draft NCD on 11 January, moments before Lilly CEO David Ricks took the virtual stage at the J.P. Morgan Healthcare Conference, where he said the proposed decision limiting Medicare coverage to patients enrolled in qualifying clinical trials is a worse scenario than Lilly expected.

“It looks like they're calling for coverage with evidence development, which isn't one of those middle scenarios that we had...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.